Phage-derived fully human antibody scFv fragment directed against human vascular endothelial growth factor receptor 2 blocked its interaction with VEGF

Biotechnology Progress
Juan ZhangMin Wang

Abstract

Vascular endothelial growth factor receptor 2 (VEGFR-2) plays a critical role in tumor angiogenesis. None therapeutic antibodies targeting VEGFR-2 are available in clinical use. Herein, we describe the screening of a new single-chain antibody fragment (scFv) targeting extracellular domain 3 of human VEGFR-2 (kinase insert domain-containing receptor [KDR]3) from Griffin phage display scFv library. A comprehensive sequence analysis was performed to assign the framework and complementary-determining regions. The scFv exerted particular binding sites to KDR3 on molecular docking, and the binding affinity was further convinced by binding analysis both in quantitative ELISA and real-time kinetic determination by biosensors (K(D) = 40 nM). Finally, the scFv was revealed to inhibit VEGF-stimulated proliferation of human umbilical vein endothelial cells (HUVECs; IC(50) = 5 nM) and to inhibit HUVEC migration significantly at 17 nM. Taken together, our results indicate that we have successfully isolated a scFv which differentially recognizes KDR3 and has potential clinical applications in the treatment of angiogenesis related diseases.

References

Dec 5, 1991·Journal of Molecular Biology·J D MarksG Winter
May 10, 2001·Cell Structure and Function·M Shibuya
Jan 10, 2003·Nucleic Acids Research·John WestbrookHelen M Berman
Jun 5, 2003·Proteins·Rong ChenZhiping Weng
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Jun 25, 2004·Nucleic Acids Research·Stephen R ComeauCarlos J Camacho
Dec 9, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel J Hicklin, Lee M Ellis
Sep 1, 2005·Journal of the American Geriatrics Society·Evan Y Snyder, Jeanne F Loring
Nov 23, 2005·Bioinformatics·Konstantin ArnoldTorsten Schwede
Nov 23, 2005·Oncology·Michael S Gordon, David Cunningham
Dec 15, 2006·The New England Journal of Medicine·Alan SandlerDavid H Johnson
Dec 7, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·N C TonG C Jayson
Apr 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leonard B SaltzJim Cassidy
Jul 30, 2008·Journal of Structural Biology·Caterina ArcangeliVittorio Rosato
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henry S FriedmanTimothy Cloughesy
Jul 14, 2010·Future Oncology·Jennifer L SpratlinJohn R Mackey
Jul 20, 2010·Journal of Molecular Graphics & Modelling·Jonathan D Hirst, Jeffry D Madura
Aug 17, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Atsushi OhtsuYoon-Koo Kang
Sep 16, 2011·Expert Review of Anticancer Therapy·David Planchard
Dec 17, 2011·Biotechnology and Applied Biochemistry·Berrin ErdagKemal Baysal

❮ Previous
Next ❯

Citations

Jul 3, 2013·Drug Design, Development and Therapy·Hsin-chung LeeAkon Higuchi
Aug 22, 2012·Human Vaccines & Immunotherapeutics·Justyna BazanAndrzej Gamian
Apr 26, 2016·Acta Pharmacologica Sinica·Lin MaH Eric Xu
Oct 27, 2015·Nanoscale·Ju Hun LeeSeung-Wuk Lee
Apr 19, 2019·Journal of Cellular Biochemistry·Mehdi Asghari VostakolaeiJalal Abdolalizadeh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.